Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | ATP4A | P20648 | 3/20 | 0.48 |
| ▸ | ATP4B | P51164 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 3/20 | 0.44 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1915273 | 0.81 | LMNA (0.60) | NPC1RAB9AL3MBTL1GSTO1CYP1A1 | |
| SCHEMBL12066366 | 0.79 | NPC1 (0.52) | NPC1RAB9AL3MBTL1GSTO1CYP1A1 | |
| SCHEMBL21350016 | 0.79 | TYR (0.58) | NPC1RAB9AL3MBTL1GSTO1CYP1A1 | |
| SCHEMBL1915382 | 0.79 | ALDH1A1 (0.58) | NPC1RAB9AL3MBTL1GSTO1CYP1A1 | |
| SCHEMBL37686 | 0.78 | NPC1 (0.63) | NPC1RAB9AL3MBTL1GSTO1CYP1A1 | |
| SCHEMBL1915377 | 0.77 | CCNK (0.54) | NPC1RAB9AL3MBTL1GSTO1CYP1A1 | |
| SCHEMBL30294201 | 0.76 | SMN1; SMN2 (0.58) | NPC1RAB9AL3MBTL1GSTO1CYP1A1 | |
| SCHEMBL19631456 | 0.76 | SMN1; SMN2 (0.58) | NPC1RAB9AL3MBTL1GSTO1CYP1A1 | |
| SCHEMBL1916379 | 0.76 | NPC1 (0.58) | NPC1RAB9AL3MBTL1GSTO1CYP1A1 | |
| SCHEMBL2026477 | 0.76 | GSTO1 (0.52) | NPC1RAB9AL3MBTL1GSTO1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | NPC1 28/4885RAB9A 1681/4885L3MBTL1 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.